Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-08-08, 19:00
